A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture； extruding the semi-solid mixture； and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.一種促細胞凋亡固體分散劑包含呈基本上非結晶形式的如本文定義之式I之Bcl-2家族蛋白抑制化合物分散於包含(a)醫藥學上可接受之水溶性聚合物載劑及(b)醫藥學上可接受之界面活性劑的固體基質中。一種製備此固體分散劑之方法包含使式I化合物、水溶性聚合物載劑及.界面活性劑經受高溫，得到可擠製之半固體混合物；擠製該半固體混合物；及冷卻所得擠出物，得到包含聚合物載劑及界面活性劑且具有該化合物呈基本上非結晶形式分散於其中之固體基質。該固體分散劑適於經口投與有需要之個體以治療特徵為一或多種抗細胞凋亡Bcl-2家族蛋白過度表現之疾病，例如癌症或免疫或自體免疫疾病。
